Beta
164324

Chicken Egg Yolk-IgY: Passive Immunization Promising Targeted Therapy of COVID-19 Pandemic

Article

Last updated: 25 Dec 2024

Subjects

-

Tags

Immunology and Vaccinology

Abstract

The world is threatened by the lethal effects of Coronaviruses (CoVs) that associated with major respiratory disorders. The CoVs are large, enveloped, positive-stranded RNA and therefore, it is considered a complicated virus structure. The spike (S) is the major protein that exists in CoV's structure regulates the viral access to the host using angiotensin-converting enzyme 2 (ACE2) receptor for both severe acute respiratory syndrome Coronaviruses-2 (SARS-CoV-2) and/or SARS-CoV initiates the animal/human disease and elevated immune responses. The receptor binding domain (RBD) in the S-proteins is essential for the CoVs-gene sequences; however the literature discussed CoV S-protein in relation to receptor-binding is little. Therefore, finding a natural antiviral to limit the spreading of CoVs is important. Herein, Immunoglobulin (Ig) Y is considered a kind of passive immunizations, represents 60% of the egg-yolk and can preventing many infectious diseases due to the particularities of IgY-molecule shape functional bioactivity to combat the pathogens. Comparing IgY to other Ig(s) antibodies, it makes the minimal animal stress, produces the lowest responses to mammalian factors. Besides, IgY is the most cost-effective extraction using the precipitation which is efficient protocol produce about (95% purity) of antibodies. We reported that IgY has a killing power to bacterial infections in broilers which beneficial to produce hygienic meat. Also, IgY-technology has a global application for treatment of viral infections and cancers. Interestingly, the anti-SARS CoV-2 single-chain fragments variable (scFv) IgY-antibodies can separate the virus from the host cell ACE2-and RBD-receptors. The expressed scFv-antibody can be assigned to be a specific-antigen binding for the potential neutralization which make a better understanding of the host-cycle range of SARS-CoV2 to adapt the ACE2 for the SARS-CoV-2 infection. Therefore, we concluded in this review that the IgY is promising to be a therapeutic target of a novel Coronaviruses disease-19 (COVID-19) pandemic.

DOI

10.21608/javs.2021.164324

Keywords

COVID-19, Egg-yolk, Immunoglobulin Y, Passive immunity, Therapy

Authors

First Name

Ibrahim

Last Name

Rehan

MiddleName

-

Affiliation

Department of Husbandry and Development of Animal Wealth, Faculty of Veterinary Medicine, Menofia University, Shebin Alkom, Menofia, Egypt.

Email

ibrahim.rehan@vet.menofia.edu.eg

City

-

Orcid

0000-0002-5632-0199

First Name

Asmaa

Last Name

Elnagar

MiddleName

-

Affiliation

Department of Biochemistry, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt.

Email

dr_smsma21488@yahoo.com

City

-

Orcid

0000-0002-4282-8047

Volume

6

Article Issue

2

Related Issue

22649

Issue Date

2021-04-01

Receive Date

2021-03-11

Publish Date

2021-04-01

Page Start

67

Page End

91

Print ISSN

1687-4072

Online ISSN

2090-3308

Link

https://javs.journals.ekb.eg/article_164324.html

Detail API

https://javs.journals.ekb.eg/service?article_code=164324

Order

9

Type

Review Article

Type Code

1,129

Publication Type

Journal

Publication Title

Journal of Applied Veterinary Sciences

Publication Link

https://javs.journals.ekb.eg/

MainTitle

Chicken Egg Yolk-IgY: Passive Immunization Promising Targeted Therapy of COVID-19 Pandemic

Details

Type

Article

Created At

22 Jan 2023